Shares of CG Oncology catapulted Monday after the biotech unveiled promising results for a J&J-rivaling bladder cancer ...

We recently published an article titled Why Traders Flocked to These 10 Stocks on Monday. In this article, we are going to ...

CG Oncology, Inc. (NASDAQ:CGON) announced on Saturday that cretostimogene grenadenorepvec monotherapy data were presented at ...

CG Oncology shares rose Monday after the company shared positive data from a study of its bladder-cancer treatment. The stock gained 39% to $31.10 in premarket trading.

Shares of CG Oncology Inc. gained 25% April 28 on the back of phase III data presented at the American Urological Association meeting over the weekend showing its cretostimogene grenadenorepvec ...

Henry Khederian CG Oncology Touts Encouraging Data From Late-Stage Study Of Bladder Cancer Candidate CG Oncology's BOND-003 trial reveals durable efficacy of cretostimogene in NMIBC patients ...

Scotiabank initiated coverage of CG Oncology (CGON) with a Sector Perform rating and $23 price target The company is developing a novel ...

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company dedicated to developing and commercializing innovative bladder-sparing therapeutics for bladder cancer patients. The company is ...

Bladder cancer is the sixth most common form of cancer ... been established by the FDA or any other health authority. About CG Oncology CG Oncology is a late-stage clinical biopharmaceutical ...

March 31, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ ... backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Late-breaking clinical and first ...

Morningstar brands and products Company Portfolio ...

CG Oncology’s primary focus has been on advancing Creto through ... Targeted approach: The specificity of oncolytic viruses in targeting cancer cells while sparing healthy tissue could potentially ...